By David Wallace – September 23, 2026 Mimrylo (rusfertide) has been added as a Category 1 treatment option for both low- and high-risk polycythemia vera (PV) in the National Comprehensive Cancer Network’s updated guidelines. For patients who need frequent phlebotomies, the update is another reason to ask whether a medicine designed to control hematocrit could […]
FDA Approves BESREMi for Essential Thrombocythemia (ET)
By David Wallace | September 13, 2026 The FDA approved BESREMi for essential thrombocythemia on August 31, 2026, giving adults with ET their first new FDA-approved treatment in nearly 30 years. BESREMi (ropeginterferon alfa-2b-njft) is a long-acting interferon given by injection every two weeks. If hydroxyurea is not controlling your disease or its side effects […]
FDA Approves Mimrylo (Rusfertide) for Polycythemia Vera
By David Wallace – September 1, 2026 The U.S. Food and Drug Administration approved Mimrylo™ (mim-rahy-loh), the brand name for rusfertide, on August 28, 2026, for the treatment of erythrocytosis in adults with polycythemia vera (PV). Erythrocytosis means the body is making too many red blood cells. Mimrylo is the first FDA-approved hepcidin mimetic for […]
SURPASS-ET: Earlier Ropeginterferon Shows 2-Year Benefit
by David Wallace September 1, 2026 Update Big news for the ET community: The FDA has approved BESREMi® for adults with essential thrombocythemia (ET). Stay tuned for our detailed article explaining what this approval could mean for patients. Two-year results from the Phase 3 SURPASS-ET trial suggest that earlier initiation of ropeginterferon alfa-2b may provide […]
